2,271 results on '"Mills, Gordon"'
Search Results
2. A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies
3. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
4. C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer
5. MIM-CyCIF: masked imaging modeling for enhancing cyclic immunofluorescence (CyCIF) with panel reduction and imputation
6. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response
7. UBA1 inhibition sensitizes cancer cells to PARP inhibitors
8. Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit
9. Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance
10. Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma
11. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
12. Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression
13. Author Correction: Stiff matrix induces exosome secretion to promote tumour growth
14. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
15. MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
16. Selective enrichment of plasma cell-free messenger RNA in cancer-associated extracellular vesicles
17. Single-cell trajectory analysis reveals a CD9 positive state to contribute to exit from stem cell-like and embryonic diapause states and transit to drug-resistant states
18. Actionability classification of variants of unknown significance correlates with functional effect
19. PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models
20. Enhancing anticancer activity of macrophages through rational drug combinations
21. Supervised learning of high-confidence phenotypic subpopulations from single-cell data
22. Stiff matrix induces exosome secretion to promote tumour growth
23. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma
24. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity
25. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches
26. Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma
27. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
28. Multi-omics characterization of silent and productive HPV integration in cervical cancer
29. Lysophosphatidic acid-induced amphiregulin secretion by cancer-associated fibroblasts augments cancer cell invasion
30. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer
31. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia
32. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
33. Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival
34. Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor–resistant NRAS-mutant melanoma.
35. RAC1 -Amplified and RAC1 -A159V Hotspot-Mutated Head and Neck Cancer Sensitive to the Rac Inhibitor EHop-016 In Vivo: A Proof-of-Concept Study.
36. Identifying therapeutic strategies for triple-negative breast cancer via phosphoproteomics.
37. Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
38. Whole-chromosome arm acquired uniparental disomy in cancer development is a consequence of isochromosome formation
39. Profiling of immune features to predict immunotherapy efficacy
40. HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors
41. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
42. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets
43. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
44. A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses
45. L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary
46. A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis
47. Precision oncology for breast cancer through clinical trials
48. Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways
49. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors
50. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.